Luis Pina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luis Pina has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
G. Zornoza
Clínica Universitaria de Navarra, Pamplona
2 shared publications- Alejandra García-Baizán
Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
1 shared publication - Ana Ezponda
Department of Radiology, Clinica Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication - Antonio Antón
Hospital Universitario Miguel Servet, Zaragoza, Spain
1 shared publication - Antonio Llombart-Cussac
Medica Scientia Innovation Research (MedSIR), Barcelona, Spain
1 shared publication - Antonio Martínez-Cuesta
Clinica Universitaria de Navarra
1 shared publication
Latest Publications
- 12 April 2022
- Published by Elsevier in Radiología (English Edition)
- Vol. 64, 2-3
Breast radiology: New horizons in times of pandemics
- 12 April 2022
- Published by Elsevier in Radiología (English Edition)
- Vol. 64, 2-3
Breast radiology: New horizons in times of pandemics
- Open Access
Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer
This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with primary stage II/III BC received bevacizumab 15 mg/kg (cycle 1; C1), then four cycles of neoadjuvant docetaxel doxorubicin, and bevacizumab every 3 weeks (C2–C5). Tumour proliferation and hypoxic status were evaluated using 18F-fluoro-3′-deoxy-3′-L-fluorothymidine (FLT)- and 18F-fluoromisonidazole (FMISO)-positron emission tomography (PET) at baseline, and during C1 and C5. Pre- and post-bevacizumab vascular changes were evaluated using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Molecular biomarkers were assessed using microarray analysis. A total of 70 patients were assessed for treatment efficacy. Significant decreases from baseline in tumour proliferation (FLT-PET), vascularity, and perfusion (DCE-MRI) were observed during C1 (p ≤ 0.001), independent of tumour subtype. Bevacizumab treatment did not affect hypoxic tumour status (FMISO-PET). Significant changes in the expression of 28 genes were observed after C1. Changes in vascular endothelial growth factor receptor (VEGFR)-2p levels were observed in 65 patients, with a > 20% decrease in VEGFR-2p observed in 13/65. Serial imaging techniques and molecular gene profiling identified several potentially predictive biomarkers that may predict response to neoadjuvant bevacizumab therapy in BC patients.
Open AccessEarly Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer
This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with primary stage II/III BC received bevacizumab 15 mg/kg (cycle 1; C1), then four cycles of neoadjuvant docetaxel doxorubicin, and bevacizumab every 3 weeks (C2–C5). Tumour proliferation and hypoxic status were evaluated using 18F-fluoro-3′-deoxy-3′-L-fluorothymidine (FLT)- and 18F-fluoromisonidazole (FMISO)-positron emission tomography (PET) at baseline, and during C1 and C5. Pre- and post-bevacizumab vascular changes were evaluated using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Molecular biomarkers were assessed using microarray analysis. A total of 70 patients were assessed for treatment efficacy. Significant decreases from baseline in tumour proliferation (FLT-PET), vascularity, and perfusion (DCE-MRI) were observed during C1 (p ≤ 0.001), independent of tumour subtype. Bevacizumab treatment did not affect hypoxic tumour status (FMISO-PET). Significant changes in the expression of 28 genes were observed after C1. Changes in vascular endothelial growth factor receptor (VEGFR)-2p levels were observed in 65 patients, with a > 20% decrease in VEGFR-2p observed in 13/65. Serial imaging techniques and molecular gene profiling identified several potentially predictive biomarkers that may predict response to neoadjuvant bevacizumab therapy in BC patients.
- 1 April 2019
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 57, 317-322
Is it worth to perform preoperative MRI for breast cancer after mammography, tomosynthesis and ultrasound?
- 1 April 2019
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 57, 317-322
Is it worth to perform preoperative MRI for breast cancer after mammography, tomosynthesis and ultrasound?
- 1 October 2018
- Published by Elsevier in Revista de Senología y Patología Mamaria
- Vol. 31 (4) , 121-122
Intervencionismo mamario guiado por imagen: ¿dónde estamos?
- 1 October 2018
- Published by Elsevier in Revista de Senología y Patología Mamaria
- Vol. 31 (4) , 121-122
Intervencionismo mamario guiado por imagen: ¿dónde estamos?
- 1 November 2014
- Published by Elsevier in Radiologia
- Vol. 56 (6) , 479-484
Cribado poblacional de cáncer de mama. Certezas, controversias y perspectivas de futuro
- 1 November 2014
- Published by Elsevier in Radiologia
- Vol. 56 (6) , 479-484
Cribado poblacional de cáncer de mama. Certezas, controversias y perspectivas de futuro
- Open Access
- 15 April 2011
- Published by Springer Nature in Insights into Imaging
- Vol. 2 (4) , 493-500
Ultrasound-guided core-needle biopsy of breast lesions
Objective: To review the role of ultrasound-guided core-needle biopsy (CNB) in the management of breast lesions. Methods: Review of the most relevant literature on this topic. Results: This technique shows a high sensitivity value of about 97.5% and it offers many advantages over other imaging techniques to guide a biopsy: non-ionising radiation, low cost, full control of the needle in real time, accessibility in difficult locations, multidirectional punctures and excellent comfort for patients and radiologists. All of these advantages have made this technique the most widespread used to perform a biopsy for a suspicious breast lesion. The most important limitation is the failure to perform a biopsy for lesions that are not seen on ultrasound. An adequate radiological–pathological correlation is necessary to minimise the false-negative results. Conclusion: Ultrasound-guided CNB has proven to be a reliable technique for performing a biopsy for breast lesions that can be clearly seen on ultrasound.
- 15 April 2011
- Published by Springer Nature in Insights into Imaging
- Vol. 2 (4) , 493-500
Open AccessUltrasound-guided core-needle biopsy of breast lesions
Objective: To review the role of ultrasound-guided core-needle biopsy (CNB) in the management of breast lesions. Methods: Review of the most relevant literature on this topic. Results: This technique shows a high sensitivity value of about 97.5% and it offers many advantages over other imaging techniques to guide a biopsy: non-ionising radiation, low cost, full control of the needle in real time, accessibility in difficult locations, multidirectional punctures and excellent comfort for patients and radiologists. All of these advantages have made this technique the most widespread used to perform a biopsy for a suspicious breast lesion. The most important limitation is the failure to perform a biopsy for lesions that are not seen on ultrasound. An adequate radiological–pathological correlation is necessary to minimise the false-negative results. Conclusion: Ultrasound-guided CNB has proven to be a reliable technique for performing a biopsy for breast lesions that can be clearly seen on ultrasound.
- 5 April 2007
- Published by Wiley in Australasian Radiology
- Vol. 51 (2) , 133-138
Metastases to the breast: A review of 33 cases
Summary: The aim of the study was to show the clinical and radiological manifestations of metastases to the breast (MB). From 1987 to 2006, 33 patients with MB were diagnosed at our institution. Their clinical and radiological features were retrospectively evaluated. Of the 33 cases, 31 presented as a palpable breast lump. On mammography, their findings were classified as follows: well‐circumscribed masses (11 cases), ill‐circumscribed masses (five), focal asymmetric densities (one) and inflammatory skin changes (six). Mammograms were normal in six cases (all of them showed dense breast tissue). Four CT scans showed two well‐circumscribed masses and two ill‐circumscribed masses. Ultrasonography was available in 18 cases: hypoechoic lesions (15 cases) were more frequent than hyperechoic (one) or isoechoic lesions (two). The appearance on magnetic resonance was similar to primary breast cancer (one case). The most common primary tumours causing MB were haematological malignancies (nine cases) and melanomas (seven). Metastases to the breast showed a wide range of mammographic and ultrasonographic appearances, resembling both benign and malignant lesions. Any patient who presents with a breast lump with a history of cancer should undergo a core‐needle biopsy in order to determine the histology of the lump.
- 5 April 2007
- Published by Wiley in Australasian Radiology
- Vol. 51 (2) , 133-138
Metastases to the breast: A review of 33 cases
Summary: The aim of the study was to show the clinical and radiological manifestations of metastases to the breast (MB). From 1987 to 2006, 33 patients with MB were diagnosed at our institution. Their clinical and radiological features were retrospectively evaluated. Of the 33 cases, 31 presented as a palpable breast lump. On mammography, their findings were classified as follows: well‐circumscribed masses (11 cases), ill‐circumscribed masses (five), focal asymmetric densities (one) and inflammatory skin changes (six). Mammograms were normal in six cases (all of them showed dense breast tissue). Four CT scans showed two well‐circumscribed masses and two ill‐circumscribed masses. Ultrasonography was available in 18 cases: hypoechoic lesions (15 cases) were more frequent than hyperechoic (one) or isoechoic lesions (two). The appearance on magnetic resonance was similar to primary breast cancer (one case). The most common primary tumours causing MB were haematological malignancies (nine cases) and melanomas (seven). Metastases to the breast showed a wide range of mammographic and ultrasonographic appearances, resembling both benign and malignant lesions. Any patient who presents with a breast lump with a history of cancer should undergo a core‐needle biopsy in order to determine the histology of the lump.
- Open Access
- 1 December 2004
- Published by SciELO Espana/Repisalud in Anales del Sistema Sanitario de Navarra
- Vol. 27 (3) , 345-358
Técnicas de biopsia para el diagnóstico de lesiones mamarias no palpables
- 1 December 2004
- Published by SciELO Espana/Repisalud in Anales del Sistema Sanitario de Navarra
- Vol. 27 (3) , 345-358
Open AccessTécnicas de biopsia para el diagnóstico de lesiones mamarias no palpables
- 2 February 2002
- Published by Springer Nature in European Radiology
- Vol. 12 (7) , 1703-1710
An experience with the Advanced Breast Biopsy Instrumentation (ABBI) system in the management of non-palpable breast lesions
Our objective was to evaluate our experience with the Advanced Breast Biopsy Instrumentation system (ABBI) in non-palpable breast lesions in a prospective study from July 1998 to November 2000. The ABBI system was included in a protocol for BIRADS 4 non-palpable, small (
- 2 February 2002
- Published by Springer Nature in European Radiology
- Vol. 12 (7) , 1703-1710
An experience with the Advanced Breast Biopsy Instrumentation (ABBI) system in the management of non-palpable breast lesions
Our objective was to evaluate our experience with the Advanced Breast Biopsy Instrumentation system (ABBI) in non-palpable breast lesions in a prospective study from July 1998 to November 2000. The ABBI system was included in a protocol for BIRADS 4 non-palpable, small (